Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 292152
                    [Title] => Therapharma’s losartan brand marks first year
                    [Summary] => Therapharma, a unit of United Laboratories, recently celebrated the first year of its brand of losartan, a medicine for high blood pressure.


Losartan belongs to a new class of antihypertensive medicine called angiotensin receptor blocker (ARB).


According to Dr. Esperanza Cabral, past president of Philippine Society of Hypertension, several studies have shown that losartan is effective in lowering blood pressure and helps delay the onset of kidney problems.


Compared with other types of blood pressure medicines, losartan has lesser side effects of cough and rash.

                    [DatePublished] => 2005-08-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 273901
                    [Title] => Pharmacoeconomic ARB out in the market soon
                    [Summary] => High blood pressure is one of the most common medical conditions in the world today, but its treatment continues to be one of physicians’ greatest challenges.  


Doctors and hypertensive patients welcome antihypertensive drugs which are effective, well-tolerated by the patients and are affordable.


Studies are now focused on the newer class of antihypertensive drugs such as the angiotensin receptor blockers (ARB).  


                    [DatePublished] => 2005-04-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 250726
                    [Title] => New brand of felodipine ‘bioequivalent’
                    [Summary] => For patients‚ the more expensive the medicine, the better is the quality.  But with the introduction of pharmacoeconomics, this kind of thinking is being corrected.


One of the main concepts of pharmacoeconomics is to provide affordable, yet bioequivalent drugs. Dr. Esperanza Cabral, president of the Philippine Society of Hypertension, provided an explanation on bioequivalence among drugs, saying price has really nothing to do with a medicine’s effectiveness.  


                    [DatePublished] => 2004-05-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 169561
                    [Title] => New directions in blood pressure control
                    [Summary] => More than 7,000 hypertension experts from all over the world convened recently in Prague, Czechoslovakia to discuss new directions in preventing complications of high blood pressure (BP), primarily stroke and heart attack. It was the joint meeting of the International Society of Hypertension (ISH) and European Society of Hypertension.


                    [DatePublished] => 2002-07-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1670819
                    [AuthorName] => Rebecca Castillo, Md.(The CHARTER Bureau)
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ANTIHYPERTENSIVE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 292152
                    [Title] => Therapharma’s losartan brand marks first year
                    [Summary] => Therapharma, a unit of United Laboratories, recently celebrated the first year of its brand of losartan, a medicine for high blood pressure.


Losartan belongs to a new class of antihypertensive medicine called angiotensin receptor blocker (ARB).


According to Dr. Esperanza Cabral, past president of Philippine Society of Hypertension, several studies have shown that losartan is effective in lowering blood pressure and helps delay the onset of kidney problems.


Compared with other types of blood pressure medicines, losartan has lesser side effects of cough and rash.

                    [DatePublished] => 2005-08-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 273901
                    [Title] => Pharmacoeconomic ARB out in the market soon
                    [Summary] => High blood pressure is one of the most common medical conditions in the world today, but its treatment continues to be one of physicians’ greatest challenges.  


Doctors and hypertensive patients welcome antihypertensive drugs which are effective, well-tolerated by the patients and are affordable.


Studies are now focused on the newer class of antihypertensive drugs such as the angiotensin receptor blockers (ARB).  


                    [DatePublished] => 2005-04-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 250726
                    [Title] => New brand of felodipine ‘bioequivalent’
                    [Summary] => For patients‚ the more expensive the medicine, the better is the quality.  But with the introduction of pharmacoeconomics, this kind of thinking is being corrected.


One of the main concepts of pharmacoeconomics is to provide affordable, yet bioequivalent drugs. Dr. Esperanza Cabral, president of the Philippine Society of Hypertension, provided an explanation on bioequivalence among drugs, saying price has really nothing to do with a medicine’s effectiveness.  


                    [DatePublished] => 2004-05-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 169561
                    [Title] => New directions in blood pressure control
                    [Summary] => More than 7,000 hypertension experts from all over the world convened recently in Prague, Czechoslovakia to discuss new directions in preventing complications of high blood pressure (BP), primarily stroke and heart attack. It was the joint meeting of the International Society of Hypertension (ISH) and European Society of Hypertension.


                    [DatePublished] => 2002-07-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1670819
                    [AuthorName] => Rebecca Castillo, Md.(The CHARTER Bureau)
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Therapharma’s losartan brand marks first year

August 18, 2005 - 12:00am

Therapharma, a unit of United Laboratories, recently celebrated the first year of its brand of losartan, a medicine for high blood pressure. Losartan belongs to a new class of antihypertensive medicine called angiotensin...

Science and Environment

Pharmacoeconomic ARB out in the market soon

April 14, 2005 - 12:00am

High blood pressure is one of the most common medical conditions in the world today, but its treatment continues to be one of physicians’ greatest challenges. Doctors and hypertensive patients welcome antihypertensive...

Science and Environment

New brand of felodipine ‘bioequivalent’

May 20, 2004 - 12:00am

For patients‚ the more expensive the medicine, the better is the quality. But with the introduction of pharmacoeconomics, this kind of thinking is being corrected. One of the main concepts of pharmacoeconomics...

Science and Environment

New directions in blood pressure control

By Rebecca Castillo, Md.(The CHARTER Bureau) | July 25, 2002 - 12:00am

More than 7,000 hypertension experts from all over the world convened recently in Prague, Czechoslovakia to discuss new directions in preventing complications of high blood pressure (BP), primarily stroke and heart...

Science and Environment